Eribulin mesylate (Halaven(R)): a new hope for pretreated patients with advanced and metastatic breast cancer
2015
Abstract
Eribulin is a non-taxane microtubule dynamics inhibitor. It is a synthetic analogue of halichondrin B.
By acting on microtubules, eribulin has an antimitotic effect in the G2/M phase of cell cycle, disrupting the mitotic spindle and inducing apoptosis. It specifically inhibits the growth phase of microtubules and sequesters tubulin in non-productive aggregates.
Recently, the results of preclinical research of "non-mitotic" mechanism of action of eribulin (particularly the effect on tumour vascularization, epithelial-mesenchymal transition, invasiveness, and migration ability) have been published.